Published in
American Society of Hematology, Blood Advances, 1(5), p. 66-70, 2021
DOI: 10.1182/bloodadvances.2020003366
Links
Tools
Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post–unrelated HCT
Journal article published in 2021 by
Yiwen Wang,
Weiyin Zhou,
Junke Wang,
Ezgi Karaesmen 
,
Hancong Tang,
Philip L. McCarthy ,
Marcelo C. Pasquini ,
Youjin Wang,
Lisa J. McReynolds,
Hormuzd A. Katki,
Mitchell J. Machiela,
Meredith Yeager,
Loreall Pooler,
Xin Sheng ,
Christopher A. Haiman
and other authors.
,
Hancong Tang,
Philip L. McCarthy ,
Marcelo C. Pasquini ,
Youjin Wang,
Lisa J. McReynolds,
Hormuzd A. Katki,
Mitchell J. Machiela,
Meredith Yeager,
Loreall Pooler,
Xin Sheng ,
Christopher A. Haiman
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Pre-HCT mosaicism is related to increased relapse risk and lower survival after unrelated HCT, independent of cytogenetics at diagnosis. Pre-HCT mosaicism could be a useful clinical tool to guide risk stratification in acute lymphoblastic leukemia patients.